🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "huge turning point" in the battle against drug-resistant strains of the bacteria, according to health experts.

A Worldwide Challenge

Gonorrhoea infections are increasing around the world, with data suggesting over 82 million infections annually. Especially elevated rates are observed in Africa and countries within the WHO's designated area, which includes China and Mongolia to New Zealand. In England, cases have reached a record high, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The approval of new treatments for gonorrhoea is an important and timely development in the context of increasing worldwide cases, increasing antimicrobial resistance and the very limited therapeutic options presently on offer.”

Health officials are increasingly worried about the increase in drug-resistant strains. The WHO has classified it as a "priority pathogen". Recent surveillance revealed that the effectiveness of key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Therapies Gain Approval

One new antibiotic, marketed under the name a brand name, was approved by the American regulatory agency in recent days for combating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Experts believe that specific application of this new drug will help slow the emergence of superbugs.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This drug, which is employed against urinary tract infections, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Development Model

This new treatment emerged from a innovative non-profit model for antibiotic development. The non-profit organisation GARDP worked alongside the pharmaceutical company its industry partner to see it through.

“This milestone signifies a significant shift in the management of highly resistant gonorrhoea, which up to this point has been staying ahead of our drug pipeline.”

Research Study Results and Worldwide Availability

Based on data detailed in a prominent scientific publication, the new drug successfully treated over nine in ten of cases of the STI. This puts it on an comparable level with the current standard treatment, which involves two antibiotics. The trial enrolled hundreds of patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the ability to license and sell the drug in numerous low-income and middle-income countries.

Medical professionals treating patients have voiced optimism. Having a one-pill regimen such as this is hailed as a "revolutionary step" for managing the epidemic. This is considered essential to lessen the impact of the disease for people and to stop the proliferation of extremely resistant gonorrhoea worldwide.